Natalizumab Modifies Catecholamines Levels Present in Patients with Relapsing- Remitting Multiple Sclerosis

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|22|31|4876-4880

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.22, Iss.31, 2016-09, pp. : 4876-4880

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cost-Effectiveness Analyses of Natalizumab (Tysabri ® ) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK

By Gani Ray  

PharmacoEconomics, Vol. 26, Iss. 7, 2008-01 ,pp. : 617-627

Adis International

Access to resources Recommend Favorite

Cladribine tablets for the treatment of relapsing–remitting multiple sclerosis

By Comi Giancarlo   Hartung Hans-Peter   Kurukulasuriya Nuwan C   Greenberg Steven J   Scaramozza Matthew  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 1, 2013-01 ,pp. : 123-136

Informa Healthcare

Access to resources Recommend Favorite

Emerging oral drugs for relapsing–remitting multiple sclerosis

By Gasperini Claudio   Ruggieri Serena  

Expert Opinion on Emerging Drugs, Vol. 16, Iss. 4, 2011-12 ,pp. : 697-712

Informa Healthcare

Access to resources Recommend Favorite

Cladribine Tablets: In Relapsing-Remitting Multiple Sclerosis

By Muir Victoria J.   Plosker Greg L.  

CNS Drugs, Vol. 25, Iss. 3, 2011-03 ,pp. : 239-249

Adis International

Access to resources Recommend Favorite

A Population Approach to Characterize Interferon Beta‐1b Effect on Contrast Enhancing Lesions in Patients With Relapsing Remitting Multiple Sclerosis

By  

Cpt: Pharmacometrics & Systems Pharmacology, Vol. 4, Iss. 5, 2015-05 ,pp. : 295-304

John Wiley & Sons Inc

Access to resources Recommend Favorite